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editorial
dEBRA International actively encourages partnership between patients and the research community to develop treat-
ments for epidermolysis bullosa (EB). Triennial 
conferences, such as EB2012, are important for 
identifying challenges and opportunities, estab-
lishing a research strategy, and, increasingly, 
bringing together all stakeholders to create new 
partnerships.
DEBRA International (http://www.debra-
international.org) is the alliance of national EB 
patient support groups working in well over 40 
countries to support people with the condition. 
Our main programs are the promotion and fund-
ing of research into finding effective treatments, 
working with clinical experts to improve the 
day-to-day care of patients, and assisting people 
with EB as well their organizations to be more 
effective on a national level.
The triennial research conferences organized 
by DEBRA International are a vital part of our rela-
tionship with clinicians and nonclinical research-
ers. Similar conferences had been held irregularly 
in the past, but they have been scheduled regular-
ly since 2006, when EB2006 (Featherstone, 2007) 
was held in Dublin, followed by EB2009 (Uitto 
et al., 2010) in Vienna and EB2012 in Marbella. 
These by-invitation meetings bring together the 
leading international players in EB research and 
are exceptionally effective in identifying both 
potential opportunities and barriers to progress, 
thereby determining DEBRA’s research strategy 
and priorities for the following three years. We are 
grateful to the Scientific Programme Committee, 
speakers, and delegates for consistently support-
ing these meetings and for the groundbreaking 
work they are doing in taking us toward treatments 
for EB. Anyone reading the EB2012 report in this 
issue will be impressed by the great progress being 
made in many different potential therapies.
Because EB is a rare condition—or, more 
strictly a collection of even rarer conditions—
people living with the disorder feel a strong 
responsibility to play a full part in the search 
for treatments. Patient-organization funding 
for research has been, and continues to be, an 
important driver in improving the understanding 
of EB, particularly in earlier days, when alterna-
tive funding sources were few and far between. 
Our aim then, as now, was to attract innovative 
researchers into the field, maintain their com-
mitment to EB as they progress in their careers, 
and do all we can to ensure that funding is 
available to keep up the momentum of research. 
One of the most pleasing aspects of EB2012 
was the number of senior researchers partici-
pating who received DEBRA support as young 
researchers and have since become leaders in 
the field. National initiatives independent of 
research-project grants, such as the DEBRA UK 
Fellowships and the DEBRA Austria–inspired EB 
House in Salzburg (Pohla-Gubo and Hintner, 
2010), have also played a part in supporting the 
EB research community.
From its earliest days, the members of DEBRA 
International have seen the importance of an 
international perspective in the search for treat-
ments. The mantra has always been that “we 
want to fund the best research, not just the best 
national research.” Our centralized interna-
tional peer review system, overseen by DEBRA’s 
International Medical & Scientific Advisory 
Panel, gives member groups the ability to pool 
funding, avoid duplication of effort, and main-
tain a common strategy. We are grateful to the 
many eminent researchers who have served on 
the panel over the years.
We now face new challenges. As the confer-
ence report shows (Bruckner-Tuderman et al., 
2013), exciting work is opening up the prospect 
of gene, cell, protein, and small-molecule ther-
apies that may, for the first time, transform the 
lives of patients. Although funding or facilitating 
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basic and preclinical research and early-stage clinical stud-
ies continues to be at the core of DEBRA International’s mis-
sion, we know that this is not enough to take therapies into 
the clinic. The funding and expertise required to take these 
new therapies to market do not lie in the patient group or, 
in most cases, in academia. New partners are needed from 
the pharmaceutical and biotechnology industries, as well 
as from venture capital, to take therapies forward. EB2012 
gave us the opportunity to build on the foundations created 
by EB2009 and invite more industry representatives to par-
ticipate as speakers and delegates and provide their perspec-
tive on the way forward. In previous conferences, contacts 
made between researchers and industry have led to some 
fruitful collaborations, such as the fibroblast-therapy (Wong 
et al., 2008) trial led by John McGrath in conjunction with 
Intercytex. Our expectation is that EB2012 will lead to more 
such partnerships.
This increased interest in EB shown by industry has been 
a welcome development for the patient group; companies 
are now coming to us rather than our having to pursue them. 
The presentation made during EB2012 by Mark De Souza 
of Lotus Tissue Repair (since acquired by Shire HGT) on his 
company’s program to take protein therapy from interest-
ing results in animal models into the clinic gave valuable 
insights into how the various elements—science, epidemi-
ology, production capacity, regulation, partnership with 
patients, and reimbursement—must be woven together from 
the beginning.
Another key element of DEBRA International’s strategy is 
to fund or facilitate initiatives that support and accelerate the 
research effort or the development of clinical trials: such a 
commitment will also make it more likely that external part-
ners will see EB therapy development as an attractive and 
viable investment. Our advisers on DEBRA’s Translational 
Research Advisory Panel and elsewhere have emphasized 
the importance of (i) a validated and well-documented 
natural history of the various types of EB in establish-
ing robust clinical end points, (ii) good measures of dis-
ease severity and quality of life, and (iii) health-economics 
data and patient registers specific to the condition. DEBRA 
International is already taking many of these forward; in 
addition to having commissioned clinical–end point valida-
tion studies, DEBRA hosted working groups at EB2012 on 
the development of clinical tools such as quality-of-life mea-
sures and severity scores as early steps in achieving EB com-
munity–wide consensus. These discussions continue.
DEBRA is very conscious that the main drivers in therapy 
development are innovative researchers and developments 
in technology. Our role will continue to be to work closely 
with our research colleagues to support them in their work 
and to help create a framework that fosters the advent of 
effective treatments in the clinic as quickly as possible.
The next conference—EB2015, to be held in the United 
States—is already in preparation. We are excited by the 
prospect of what the next three years will bring.
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